Molecular targeted therapies for pancreatic cancer
- 30 September 2008
- journal article
- review article
- Published by Elsevier BV in The American Journal of Surgery
- Vol. 196 (3), 430-441
- https://doi.org/10.1016/j.amjsurg.2008.04.009
Abstract
No abstract availableThis publication has 90 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Pancreatic cancer–associated stroma productionThe American Journal of Surgery, 2007
- The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR AgentsMolecular Cancer Research, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Monoclonal Antibodies in the Treatment of Non-Hodgkin???s LymphomaDrugs, 2007
- Pancreatic Cancer in the General Population: Improvements in Survival Over the Last DecadeJournal of Gastrointestinal Surgery, 2006
- Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor-κBCancer Research, 2006
- Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancerBritish Journal of Cancer, 2006
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Safety and antitumor activity of recombinant soluble Apo2 ligandJCI Insight, 1999